Qualification could follow, but only if trial sponsors fork over fresh data.
A screen in round worms identifies a novel mechanism for degradation of toxic proteins.
Two new open-access journals will cover specialized areas of Alzheimer’s research.
Epigenetic changes in the C9ORF72 promoter do not prevent disease, but they do decelerate brain atrophy and memory loss.
The newest contender in the race for a drug to rein in the β-secretase enzyme debuted with data that reflected a methodical approach to understand a drug’s performance in cerebrospinal fluid before looking for efficacy.
Treatments targeting the main pathological protein of Parkinson’s disease are moving toward the clinic, with two immunotherapies passing Phase 1 safety benchmarks.
Biogen Antibody Buoyed by Phase 1 Data and Hungry Investors Antibody Against α-Synuclein Looks Safe In Phase 1 At AD/PD Meeting, New BACE Inhibitor Struts Its Stuff D-peptides as Drugs? Protein Therapy Approaching Phase 1 Trials New Genetics Frontiers: ...
Microbleeds in the brain portend either stroke or cardiovascular events, depending on where they occur.
A novel assay detected two strains of human SOD1 in mice expressing the protein. They differed from those that formed in vitro. Researchers hope to use the technique to identify strains of other problem proteins as well.
Approximately 4 percent of familial ALS cases may be due to TBK1 mutations.
Sequences of more than 2,600 Icelanders link loss-of-function mutations in the ABCA7 gene to increased risk for Alzheimer’s.
Antibody against aggregated Aβ reported to clear out amyloid from brain, and perhaps slow cognitive decline, in people with prodromal Alzheimer’s disease.
Researchers found inherited recessive or dominant de novo mutations in people with sporadic ALS whose parents did not have the disease.
Motor neurons may be susceptible to ALS because they lack a chaperone that folds SOD1.
Phase 2 trial data show promise, say researchers.
No filters selected